Seviteronel
As of the edition of 20 October 2026, Seviteronel is a small molecule: stopped in 2021; acts on AR and CYP17A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 7, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 7 | 5 | 1 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innocrin Pharmaceutical | Lead sponsor of trials | 2011 to now |